Nestle Sells Peanut-Allergy Treatment Business to Stallergenes Greer
04 9월 2023 - 2:56PM
Dow Jones News
By Adria Calatayud
Nestle said it has sold its Palforzia peanut-allergy treatment
business to biopharmaceutical company Stallergenes Greer.
The Swiss consumer-goods company said Monday that it will
receive milestone payments and royalties from Stallergenes Greer.
The deal was closed upon signing, Nestle said.
The sale allows Nestle's health-science operations to focus on
its core strengths and key growth drivers, the unit's Chief
Executive Greg Behar said.
Nestle last year said that it would conduct a strategic review
of Palforzia after a slower-than-expected adoption by patients and
healthcare professionals.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
September 04, 2023 01:41 ET (05:41 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Nestle (PK) (USOTC:NSRGY)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Nestle (PK) (USOTC:NSRGY)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
Nestle SA (PK) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More Nestle SA (PK) News Articles